Showing posts with label gastric malt lymphoma. Show all posts
Showing posts with label gastric malt lymphoma. Show all posts

Friday, January 4, 2013

Study of regulatory T-cells in patients with gastric malt lymphoma: influence on treatment response and outcome.


Study of regulatory T-cells in patients with gastric malt lymphoma: influence on treatment response and outcome.


2012

Source

Departments of Pathology, Hospital del Mar, Barcelona, Spain ; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Abstract


PURPOSE:

FOXP3+ regulatory T cells (Treg) play an essential role in modulating host responses to tumors and infections. The role of these cells in the pathogenesis of MALT lymphomas remains unknown. The aims of the study were to quantify the number of infiltrating FOXP3+ and CD3+ cells in patients with gastric MALT lymphoma at diagnosis and to study kinetics of these cells and CD20+ tumor cells after treatment and during long-term follow-up.

METHODS:

FOXP3+, CD3+ and CD20+ cells were analyzed by immunohistochemistry and the number of cells was quantified using a micrometric ocular. Samples of 35 patients with gastric MALT lymphoma at diagnosis and after treatment were included. Diagnostic samples were compared to 19 cases of chronic gastritis and diffuse large B-cell lymphoma(DLBCL) of the stomach.

RESULTS:

The median number of FOXP3+ infiltrating cells was higher (27 cells/cm(2)) in gastric MALT patients than in DLBCL (10 cells; p = 0.162) but similar to chronic gastritis (20 cells; p = 0.605). No characteristic or specific distribution pattern of infiltrating FOXP3+ cells was found. Gastric MALT lymphoma patients responding to bacterial eradication therapy had higher number of FOXP3+ cells at study entry. Kinetics of both infiltrating FOXP3+ cells and tumor CD20+ cells were strongly dependent on the treatment administered.

DISCUSSION:

Gastric MALT lymphomas have a number of Treg cells more similar to chronic gastritis than to DLBCL. Patients with higher number of tumor infiltrating FOXP3+ cells at study entry seem to have better response to antibiotics. Kinetics of Treg and tumor cells are influenced by type of treatment.

Thursday, December 27, 2012

Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan.


Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan.


Apr 2012

Source

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. shonaka@intmed2.med.kyushu-u.ac.jp

Abstract


OBJECTIVE:

A multicentre cohort follow-up study of a large number of patients with gastric mucosa-associated lymphoid tissue (MALTlymphoma was conducted to elucidate the long-term outcome of the disease after Helicobacter pylori eradication.

METHODS:

420 patients with gastric low-grade MALT lymphoma who had undergone successful H pylori eradication and been followed up for at least 3 years were registered from 21 participating institutes. Responders to treatment were defined as patients whose post-treatment biopsies showed complete histological response (ChR) or probable minimal residual disease (pMRD). Treatment failure was defined as the status of progressive disease or lymphoma relapse after ChR/pMRD.

RESULTS:

323 patients (77%) responded to H pylori eradication. A logistic regression analysis showed that absence of H pylori, submucosal invasion determined by endoscopic ultrasonography and t(11;18)/API2-MALT1 were independent predictors of resistance to H pylori eradication. During the follow-up periods ranging from 3.0 to 14.6 years (mean 6.5 years, median 6.04 years), the disease relapsed in 10 of 323 responders (3.1%) while progressive disease was found in 27 of 97 non-responders (27%). Thus, 37 of 420 patients (8.8%) were regarded as treatment failures. Of these 37 patients, transformation into diffuse large B cell lymphoma occurred in nine patients. Among the non-responders and relapsed patients, 17 patients were subjected to a 'watch and wait' strategy while 90 patients underwent second-line treatments including radiotherapy (n=49), chemotherapy (n=26), surgical resection (n=6), chemoradiotherapy (n=5), antibiotic treatment (n=2), rituximab monotherapy (n=1) or endoscopic resection (n=1). Probabilities of freedom from treatment failure, overall survival and event-free survival after 10 years were 90%, 95% and 86%, respectively. Cox multivariate analysis revealed endoscopic non-superficial type to be an independent prognostic factor for adverse freedom from treatment failure, overall survival and event-free survival.

CONCLUSIONS:

The excellent long-term outcome of gastric MALT lymphoma after H pylori eradication was confirmed by this large-scale follow-up study.

Wednesday, November 7, 2012

H Pylori: The silent killer living inside all of us


H Pylori: The silent killer living inside all of us


By Ritu Dokania, Friday magazine
Nov 7, 2012

It’s silent, insidious and is the cause of gastric symptoms that range from the antisocial to the downright dangerous. But why do so few people know of its existence? Ritu Dokania unveils the mysterious bacteria behind your most embarrassing symptoms...

Alisha, a 30-year-old sales manager, hated going out in public. She refused offers of evenings out with her friends, bypassed busy events and dreaded business meetings with a passion.
It wasn’t that she disliked socialising – she had always been quite gregarious at heart – but chronic gastric symptoms were making her life a misery and she preferred to hide herself away.
Although her symptoms were troublesome, ranging from bloating and mild stomach pain to flatulence and belching, they didn’t seem serious enough to seek medical advice. She did some research online and decided it could be aerophagia, which is caused by swallowing too much air, and tried to treat it by avoiding carbonated drinks and putting an end to her chewing gum and smoking habits. Yet nothing seemed to help.
Several months passed and Alisha was no longer just embarrassed by her symptoms, but was feeling uncomfortable throughout the entire day, while horrible abdominal cramps had started to keep her awake at night.She arranged an appointment with Dr Denesh Gopalan, a gastroenterologist at Welcare Hospital in Dubai. He decided to test her for the little-known bacteria, H Pylori. The diagnosis was positive.
“H Pylori is one of the most widespread infections in the world and around 60 per cent of the UAE population has it,” says Dr Gopalan. “Yet most people don’t know about this silent infection until they start suffering from gastritis or the painful effects of ulcers.”
Its presence is hard to detect, but delayed discovery can give rise to a number of problems as H Pylori is associated not only with ulcers, but also with stomach cancer and gastric malt lymphoma, which is a stomach cancer affecting the white blood cells of the immune system.
Thankfully, once the cause of Alisha’s problems had been pinpointed, her infection was easy to eradicate. “She was put on a course of antibiotics for 14 days, after which the symptoms she had been suffering from for so long subsided remarkably,” says Dr Gopalan.
H Pylori, short for Helicobacter Pylori, is a spiral-shaped bacterium that resides in the stomachs of humans and animals. Although our stomachs are lined with a protective coating to keep it safe from bacterial infections, H Pylori secretes an enzyme that neutralises stomach acid, enabling the bacteria to burrow deep into the walls of our stomachs, where it may survive undetected for decades.
The damage it causes to the mucous coating allows powerful stomach acid to get through to the sensitive lining beneath. Together, the stomach acid and H Pylori irritate the lining of the stomach or duodenum, which can cause ulcers and other complications.
The link between H Pylori and ulcers was a scientific breakthrough. Scientist Barry Marshall discovered it by deliberately ingesting broth infected with the bacteria in order to prove the connection, and in 2005 he and his colleague Robin Warren were awarded the Nobel Prize in Physiology or Medicine for their discovery, which reversed decades of doctrine that ulcers were caused by spicy food and stress.
The Centers for Disease Control and Prevention in Atlanta estimates that two-thirds of the world’s population is infected with the bacterium, making it the most widespread infection in the world.
It is most likely acquired by the ingestion of contaminated food or water, which can happen via faecal matter if food is prepared by people who do not wash their hands after using the bathroom, or in poor sanitary conditions. It can spread from person to person via saliva or by sharing food utensils and is most common in socio-economic groups characterised by crowded living conditions.
Symptoms and implications
H Pylori is often asymptomatic, meaning most people with the infection will never have any signs or symptoms. When symptoms do occur they may include burping, bloating, heartburn, oesophageal reflux, diarrhoea, constipation, flatulence and upper- and mid-abdominal pain. Difficulty losing weight may also be attributed to H Pylori, Dr Gopalan says. Having the infection causes stress and eventually cortisol.
H Pylori is also the leading cause of gastritis, an inflammation of the stomach lining. It is responsible for over 90 per cent of all duodenal ulcers and nearly 80 per cent of all gastric ulcers.
“This pernicious bacteria, which survives so easily in our stomachs, should be exterminated before it does serious harm,” says Dr Gopalan. “While it can remain in the human stomach for a long time without causing any symptoms, it may manifest into more serious diseases over time – one to two per cent of infected people are at risk of stomach cancer and the cancer gastric malt lymphoma is eight times more common in people with H Pylori than in those not infected.”
Apart from these diseases, medical researchers and doctors believe that H Pylori may be implicated in a number of non-digestive conditions including cardiovascular disorders, migraine and Raynaud’s disease (impaired circulation in the hands and feet). Surprisingly, it may also cause depression and anxiety. The happy chemical, serotonin, is largely seen in a healthy digestive system and damage to your stomach by H Pylori will lead to a shortage of this important chemical.

Detection, treatment and prevention

“When I tell my patients about this bacteria, seven out of ten of them will never have heard of it before,” says Dr Gopalan. “But I am more surprised to see that even physicians often do not think to test for this bacteria when a patient complains about the common symptoms of this infection.”

A patient’s breath can be a typical warning sign, says Dr Gopalan, as reflux directly from the stomach or higher levels of periodontal gum disease caused by the bacteria can give it a strong smell. Testing for H Pylori infection may be performed on blood, stool or breath samples or through biopsies of tissue from the lining of the gastrointestinal tract obtained during endoscopy.
H Pylori is successfully eradicated in 80 per cent of cases, but it can be a tough infection to treat, says Dr Gopalan, as it often resides in the deepest layers of the stomach. It is also important that the antibiotics are prescribed carefully.
“H Pylori quickly becomes resistant to several antibiotics when given one at a time,” says Dr Gopalan. For this reason, a ‘triple therapy’ is often employed, which consists of two types of antibiotics and a proton pump inhibitor (PPI), which is used to decrease the stomach’s acidity, allowing the inflamed stomach lining to heal. The treatment is given for ten to 14 days according to the presence and severity of the infection. After a month, the test is repeated to see if the infection has cleared.
“Some antibiotics that are recommended elsewhere in the world might not be suitable in UAE due to the bacteria’s resistance pattern here,” warns Dr Gopalan. “It is advisable to check with your doctor about whether the antibiotic prescribed is the correct one for your particular geographical area.”
Since the source of H Pylori is not yet fully known, recommendations for avoiding infection have not been made. In general, it is always wise to wash hands thoroughly, only eat food that has been hygienically prepared, and drink water from a safe, clean source.
Certain nutrients, especially vitamins A, C, and E, along with zinc, protect the stomach lining by combating free radicals, so ensure that you are not deficient in any of these. Certain probiotics (healthy bacteria) such as lactobacillus and bifidobacterium may also help protect you from H Pylori.

Tuesday, August 28, 2012

Analysis of Microsatellite Instability in Gastric Malt Lymphoma.


Analysis of Microsatellite Instability in Gastric Malt Lymphoma.


Aug 2012

Abstract

Abstract In Helicobacter pylori gastritis, constant antigenic stimulation triggers a sustained B-cell proliferation. Errors made during this continuous DNA replication are supposed to be corrected by the DNA mismatch repair mechanism. Failure of this mismatch repair mechanism has been described in hereditary non-polyposis colorectal cancer (HNPCC) and results in a replication error phenotype. Inherent to their instability during replication, microsatellites are the best markers of this replication error phenotype. We aimed to evaluate the role of defects in the DNA mismatch repair mechanism and microsatellite instability (MSI) in relation to the most frequent genetic anomaly, translocation t(11;18)(q21;q21), in gastric mucosa-associated lymphoid tissue (MALTlymphoma . Therefore, we examined 10 microsatellite loci (BAT25, BAT26, D5S346, D17S250, D2S123, TGFB, BAT40, D18S58, D17S787 and D18S69) for instability in 28 patients with MALTlymphomas. In addition, these tumors were also immunostained for MLH1, MSH2, MSH6, and PMS2, as well as screened for the presence of t(11;18)(q21;q21) by real time polymerase chain reaction (RT-PCR). We found MSI in 5/28 (18%) lymphomas, with MSI occurring in both t(11;18)(q21;q21)-positive and -negative tumors. One tumor displayed high levels of instability, and, remarkably, this was the only case displaying features of a diffuse large B-cell lymphoma. All microsatellite instable lymphomas showed a loss of MSH6 expression. In conclusion, our data suggest that a MMR-defect may be involved in the development of gastric MALT lymphomas, and that a defect of MSH6 might be associated with those MSI-driven gastric lymphomas.

Monday, June 8, 2009

Primary gastric lymphoma: a retrospective series of 35 cases

Primary gastric lymphoma: a retrospective series of 35 cases

Tunis Med. 2008 May
Ennibi K, Mikdame M, Rabhi M, Jroundi I, Benkirane A, Chaari J, Toloune F.
Service de Médecine interne A. Hôpital Militaire d'Instruction Mohammed V. Rabat. Maroc.


BACKGROUND: Primary gastric non Hodgkin's lymphoma (PGNHL) is the most common site of extranodal malignant lymphoma. It is a rare subtype of malignancy, for which no consensus exists about treatment.

AIM: The purpose of This paper was to assess the managemnt of PGNHL.

METHODS: Between January 1992 and December 2001, 35 patients were retrospectively evaluated.

RESULTS: Of the 35 patients, with a mean age of 44 years old Signs and symptoms are unspecific. 20 (57.1%) were in stage IE/IIE1. 15 patients (42.8%) were in stage IIE2,IIIE,IVE. These patients were treated with primary surgery with or without chemotherapy (11; 31.4%); primary chemotherapy (CT) alone with surgery in one patient (21; 60%) and three patients with gastric MALT lymphoma were treated by Helicobacter pylori eradication. The 5 year survival rates of the 35 patients are 62, 86%. There was no significant difference in the 5 year survival rate between the patients with low grade lymphoma and the patients with large grade lymphoma (75% versus 60%, P = 0.467). The 5-year survival rates for stage I/IIE1 and IIE2/III/IV patients were 80%, 53.3% respectively (p less then p =" 0.05).

CONCLUSIONS: This study suggested that primary surgical resection may be important factor predicting the long-term survival of patients with primary gastric NHL. H. pylori eradication therapy was an effective first-line treatment for patients with gastric MALT lymphoma.

PubMed

Monday, November 24, 2008

Antibiotics Effective in Treatment of MALT Lymphoma

Antibiotics Effective in Treatment of MALT Lymphoma

Researchers from Taiwan have reported that treatment of Helicobacter pylori (H. pylori) infection with antibiotics is effective against early-stage, low-grade mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach as well as high-grade transformed tumors. The details of this study appeared in the September 21, 2005, issue of the Journal of the National Cancer Institute .

Researchers have long known that H. pylori is associated with a certain type of low-grade non-Hodgkin’s lymphoma referred to as MALT lymphoma. MALT lymphoma develops outside of lymph nodes, most commonly in the stomach, salivary glands, lungs, or thyroid. Treatment of H. pylori infection with antibiotics results in complete disappearance of lymphoma in some patients with early-stage MALT lymphoma of the stomach.

In order to further assess the role of antibiotics in the treatment of patients with early-stage MALT lymphoma of the stomach, researchers in Taiwan evaluated two groups of patients. One group had low-grade MALT lymphoma, while the other had high-grade transformed lymphoma.

The patients with high-grade lymphoma had diffuse large B-cell lymphoma (DLBCL) with features of MALT. Some have speculated that DLBCL(MALT) lymphoma is not dependent on H. pylori and will not be affected by antibiotic treatment.

A large majority of both groups of patients were infected with Helicobacter pylori —94% of the patients with low-grade lymphoma and 100% of the patients with high-grade lymphoma.

Patients were treated with two weeks of antibiotics. The antibiotics were highly effective in both groups:

Antibiotics eliminated the H. pylori infection in 97% of the low-grade patients.

H. pylori infection was eliminated in 92% of the high-grade patients.

Among those whose infection was eliminated:

80% of patients with low-grade lymphoma experienced a complete disappearance of detectable lymphoma.

64% of patients with high-grade lymphoma had a complete disappearance of their disease.
None of the patients who were initially negative for H.pylori and none who had persistent infection after antibiotic treatment experienced a complete disappearance of lymphoma. After roughly five years of follow-up, lymphoma recurred in three (13%) of the patients with low-grade lymphoma; none of the patients with high-grade lymphoma had a recurrence.
The researchers conclude that antibiotic treatment of H. pylori infection is effective for both low-grade MALT lymphoma of the stomach as well as DLBCL(MALT). They recommend additional studies to confirm that antibiotics are an appropriate first-line treatment for early stage, H. pylori-positive DLBCL(MALT).


Comments: These are very interesting results and it will be important to confirm these observations in American patients.

Reference: Chen L-T, Lin J-T, Tai JJ et al. Long-term results of anti-Helicobacter pyloritherapy in early-stage gastric high-grade transformed MALT lymphoma. Journal of the National Cancer Institute . 2005;97:1345-1353.

CancerConsultants



What is gastric MALT lymphoma?

What is gastric MALT lymphoma?
Gastric MALT lymphoma is a type of Non Hodgkin Lymphoma (NHL) affecting the stomach

Treatment options for gastric MALT lymphoma:

The following treatments can be used for gastric MALT lymphomas:
Treatment of Helicobacter pylori infection
Radiation therapy
Surgery
Chemotherapy


Let us look at how these different treatments fit in.

Treatment of H pylori infection:

Many cases of MALT lymphoma of the stomach are strongly associated with infection with H pylori, a bacterium that commonly causes gastritis and stomach ulcers. It has been seen that in those patients with MALT lymphoma who also test positive for H pylori, antibiotics for H pylori may actually control the cancer. In 3 out of 4 patients with early disease, H pylori treatment may result in a complete resolution of the tumor. The disease remains controlled in many patients. Those with complete response may be kept on regular follow-up with endoscopies. Cancer treatment may be kept in reserve for later.

Radiotherapy for MALT lymphoma:

Radiation is the preferred treatment for MALT lymphoma when H pylori is absent, or when anti H pylori treatment fails. Relatively low doses of radiation are given, and these doses nearly always control the lymphoma. Radiotherapy treatment alone can cause complete response in more than 95% of the patients, and most patients remain controlled in the long term.


Surgery for MALT lymphoma of the stomach:

Surgery is an effective treatment of MALT lymphomas of the stomach and results in long term control in most patients. The potential morbidities of surgery are higher than those of radiation, and therefore surgery is less commonly used for treatment. Like radiotherapy, surgery is usually sufficient to control and cure MALT lymphomas that are limited to the stomach.

Chemotherapy for MALT lymphoma:

Chemotherapy is generally used for early stage gstric MALT lymphomas when local teatments fail to control disease or when the disease recurs. For advanced stage lesions chemotherapy is the treatment of choice. Different combination treatments are effective in these slow growing lymphomas.

About.com